FDA tackles combo confusion

The on-again, off-again efforts of the FDA's office of combination products are back on again. The OCP's good manufacturing practices proposal is intended to clarify confusion surrounding approvals of products that comprise combinations of drugs, biologics and devices. The current work takes the place of stalled draft guidance begun in 2004.

The new proposal distinguishes products that are physically combined during manufacturing to create either single entities or two separate components in the same package (so-called co-packaging) from those that are cross-labeled, in which components are manufactured separately and packaged, but are labeled specifically for use with another product.

The confusion that the FDA is attempting to clarify concerns combinations of products that already have cGMP regulations. Manufacturers sometimes don't understand which of the existing regulations should govern. SmartConsulting Group says the revised regulations will reduce confusion regarding the "which regulations?" question and aid in enforcement consistency. Minimizing paperwork hassles is another objective.

The FDA is in the process of finalizing comments now.

- here's the article

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)